Published in Aust N Z J Med on February 01, 1998
A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol (2010) 1.70
Pregnancy outcomes and appropriate timing of pregnancy in 183 pregnancies in Korean patients with SLE. Int J Med Sci (2011) 0.93
Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: Results from a case control study and literature review. Open Rheumatol J (2008) 0.92
Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus (2009) 0.91
Cross-sectional analysis of adverse outcomes in 1,029 pregnancies of Afro-Caribbean women in Trinidad with and without systemic lupus erythematosus. Arthritis Res Ther (2007) 0.78
The role of lupus nephritis in development of adverse maternal and fetal outcomes during pregnancy. Int J Prev Med (2013) 0.76
Abnormal hypothalamic-pituitary-adrenal axis function in rheumatoid arthritis. Effects of nonsteroidal antiinflammatory drugs and water immersion. Arthritis Rheum (1994) 2.30
Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum (1999) 2.17
More emphasis on the enthesis. J Rheumatol (1989) 1.64
A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol (1988) 1.43
Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum (1998) 1.39
Churg-Strauss syndrome: the use of cyclophosphamide in mononeuritis. Rheumatology (Oxford) (2003) 1.38
Fibrositis/fibromyalgia syndrome: the key to the puzzle of chronic pain. Med J Aust (1990) 1.38
A glossary of pain terms for medicolegal work. Med J Aust (1991) 1.38
Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol (2001) 1.29
Fibromyalgia syndrome: assessment of the severity of the condition 2 years after diagnosis. J Rheumatol (1994) 1.26
Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. Arthritis Rheum (2001) 1.25
Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum (2000) 1.15
Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain (1994) 1.15
Inhibitory effect of annexin I on synovial inflammation in rat adjuvant arthritis. Arthritis Rheum (1999) 1.13
Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger? Postgrad Med J (1991) 1.11
Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (1992) 1.09
Antiinflammatory effect of lipocortin 1 in experimental arthritis. Inflammation (1997) 1.05
Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation. Clin Exp Immunol (2008) 1.05
Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol (1992) 1.04
Repetitive strain syndrome: an Australian experience. J Rheumatol (1986) 1.01
Popliteal cyst rupture in septic arthritis. Med J Aust (1982) 1.00
Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis. Clin Exp Immunol (1997) 1.00
Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol (1993) 0.99
The painful swollen calf. A comparative evaluation of four investigative techniques. Med J Aust (1986) 0.92
Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxford) (2006) 0.92
Body composition in systemic lupus erythematosus. Br J Rheumatol (1998) 0.91
Mycobacterial disease in the musculoskeletal system. Med J Aust (1987) 0.91
Differential distribution of annexins-I, -II, -IV, and -VI in synovium. Ann Rheum Dis (1995) 0.91
Jaccoud's arthritis and panvasculitis in the hypocomplementemic urticarial vasculitis syndrome. J Rheumatol (1988) 0.89
Stress system response and rheumatoid arthritis: a multilevel approach. Rheumatology (Oxford) (1999) 0.89
Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus. Rheumatology (Oxford) (1999) 0.89
The clinical significance of the anticentromere antibody. Br J Rheumatol (1987) 0.89
Eosinophilic fasciitis and aplastic anaemia. J Rheumatol (1981) 0.89
Peripheral enthesopathy in diffuse idiopathic skeletal hyperostosis (DISH): a radiologic study. J Rheumatol (1982) 0.89
Lupus and non-lupus cutaneous manifestations in systemic lupus erythematosus. Aust N Z J Med (1987) 0.87
Radiographic features of the hand in diffuse idiopathic skeletal hyperostosis (DISH): comparison with normal subjects and acromegalic patients. Radiology (1981) 0.87
Clinical comparison of cultured human epithelial cells and rat liver as substrates for the fluorescent antinuclear antibody test. J Rheumatol (1985) 0.87
Livedo reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus. Arch Dermatol (1987) 0.86
Glucocorticoid inhibition of adjuvant arthritis synovial macrophage nitric oxide production: role of lipocortin 1. Clin Exp Immunol (1998) 0.86
The association of retroperitoneal fibrosis with systemic vasculitis and HLA-B27: a case report and review of the literature. J Rheumatol (1982) 0.86
Asian ethnicity in systemic lupus erythematosus: an Australian perspective. Intern Med J (2013) 0.86
The diagnosis and classification of scleroderma (systemic sclerosis). Postgrad Med J (1988) 0.85
Sclerotherapy as treatment of recurrent bleeding from upper gastrointestinal telangiectasia in CREST syndrome. Br J Rheumatol (1993) 0.85
New bone formation in acromegaly: pathogenetic implications for diffuse idiopathic skeletal hyperostosis. Clin Exp Rheumatol (1986) 0.84
Antiphospholipid antibodies in the connective tissue diseases: their relation to the antiphospholipid syndrome and forme fruste disease. J Rheumatol (1989) 0.84
Fibromyalgia syndrome and disease activity in systemic lupus erythematosus. Lupus (1994) 0.84
Exacerbation of adjuvant arthritis by adrenalectomy is associated with reduced leukocyte lipocortin 1. J Rheumatol (1997) 0.84
Annexin I surface binding sites and their regulation on human fibroblast-like synoviocytes. Arthritis Rheum (2000) 0.84
Endogenous glucocorticoids modulate neutrophil migration and synovial P-selectin but not neutrophil phagocytic or oxidative function in experimental arthritis. Clin Exp Immunol (1998) 0.84
Diffuse idiopathic skeletal hyperostosis and new bone formation in male gouty subjects. A radiologic study. Rheumatol Int (1982) 0.83
Female adolescent rheumatological presentations: the importance of chronic pain syndromes. Aust Paediatr J (1989) 0.83
Costotransverse joint injection description of technique. Australas Radiol (1987) 0.82
Reiter's syndrome after Campylobacter jejuni enteritis. Arthritis Rheum (1980) 0.82
Severe bone marrow failure due to low dose oral methotrexate. J Rheumatol (1988) 0.82
Endogenous estrogen regulation of inflammatory arthritis and cytokine expression in male mice, predominantly via estrogen receptor alpha. Arthritis Rheum (2010) 0.82
Suppression of adjuvant arthritis and synovial macrophage inducible nitric oxide by N-iminoethyl-L-ornithine, a nitric oxide synthase inhibitor. Inflammation (1997) 0.82
Urinary excretion of the pyridinium cross-links of collagen in systemic lupus erythematosus. Clin Rheumatol (1998) 0.82
Assessment of esophageal abnormalities in progressive systemic sclerosis using radionuclide transit. J Rheumatol (1985) 0.82
Annexin I and dexamethasone effects on phospholipase and cyclooxygenase activity in human synoviocytes. Mediators Inflamm (2000) 0.82
Aminotransferase levels during treatment of rheumatoid arthritis with leflunomide in clinical practice. Ann Rheum Dis (2003) 0.81
A formyl peptide receptor agonist suppresses inflammation and bone damage in arthritis. Br J Pharmacol (2014) 0.81
Insulin and new bone formation in diffuse idiopathic skeletal hyperostosis. Clin Rheumatol (1985) 0.80
The brachial plexus tension test of Elvey. Br J Rheumatol (1990) 0.80
Central retinal vein occlusion and scleroderma: implications for sclerodermatous vascular disease. Ann Rheum Dis (1981) 0.80
Identification of a novel cell type-specific intronic enhancer of macrophage migration inhibitory factor (MIF) and its regulation by mithramycin. Clin Exp Immunol (2010) 0.79
Wegener's granulomatosis: clinical features and outcome in seventeen patients. Aust N Z J Med (1985) 0.78
Neuropsychiatric manifestations of systemic lupus erythematosus. Aust N Z J Med (1988) 0.78
The tumour suppressor gene p53 modulates the severity of antigen-induced arthritis and the systemic immune response. Clin Exp Immunol (2008) 0.78
Neurogenic flare responses in chronic rheumatic pain syndromes. Clin Exp Neurol (1987) 0.78
Focus on systemic lupus erythematosus in indigenous Australians: towards a better understanding of autoimmune diseases. Intern Med J (2013) 0.78
Idiopathic polymyositis complicated by arthritis and mesangial proliferative glomerulonephritis: case report and review of the literature. Br J Rheumatol (1993) 0.78
Marked hyperinsulinemia after glucose challenge in patients with diffuse idiopathic skeletal hyperostosis. J Rheumatol (1982) 0.78
Clinical evaluation of intra-articular injections for lumbar facet joint pain. Med J Aust (1986) 0.78
Detection of anti-DNA antibodies: a comparison between two Farr assays, Crithidia luciliae and a human chromosomal substrate assay. Br J Rheumatol (1988) 0.77
Flow cytometric detection of anti-neutrophil cytoplasmic autoantibodies. J Immunol Methods (1994) 0.77
Medical problems in joint replacement patients: a retrospective study of 243 total hip arthroplasties. Med J Aust (1990) 0.77
Endogenous glucocorticoids modulate experimental anti-glomerular basement membrane glomerulonephritis. Clin Exp Immunol (2000) 0.77
Lymphocytes from systemic lupus erythematosus patients display increased spreading on VCAM-1, an effect associated with active renal involvement. Lupus (2012) 0.76
Methotrexate use in systemic lupus erythematosus. Lupus (1997) 0.76
A comparative study of clinical signs in fibromyalgia/fibrositis syndrome, healthy and exercising subjects. J Rheumatol (1993) 0.76
The scleroderma neck sign. J Rheumatol (1989) 0.76
Combination therapy with methotrexate and sulphasalazine in rheumatoid arthritis--tolerance of therapy. Ann Rheum Dis (1994) 0.75
Hepatic reactions to nifedipine. Med J Aust (1985) 0.75
The role of sex hormones in pain response. Pain (1999) 0.75
Advances in the understanding of neuroendocrine function in rheumatic disease. Aust N Z J Med (1996) 0.75
Fibromyalgia and chronic fatigue syndrome. Curr Opin Rheumatol (1990) 0.75
The effects of dietary fibre on glucose tolerance in healthy males. Aust N Z J Med (1979) 0.75
Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice. J Rheumatol (2000) 0.75
Current thinking on fibromyalgia syndrome. Aust Fam Physician (1990) 0.75
Adult-onset Still's disease: a concise review of clues to an important rare syndrome. Aust N Z J Med (1999) 0.75
Peripheral arthralgic presentation of fibrositis/fibromyalgia syndrome. J Rheumatol (1992) 0.75
Single anticardiolipin measurement in the routine management of patients with systemic lupus erythematosus. J Rheumatol (1994) 0.75
The antiphospholipid antibody syndrome. Aust Fam Physician (1998) 0.75
Measurement of anti-DNA antibodies by ELISA: a comparative study with Crithidia and a Farr assay. Pathology (1991) 0.75
The safety and efficacy of cyclosporine (Neoral) in rheumatoid arthritis. J Rheumatol (1999) 0.75